Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Gastric or Gastroesophageal Junction Adenocarcinoma

Agilent Technologies, Inc. announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Gastric or Gastroesophageal...

Related Keywords

,Agilent Technologies Inc ,Agilent Technologies ,Gastroesophageal Junction ,Markets ,